Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Beigene Ltd (BGNE)  
$153.58 5.02 (3.38%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 90,630,000
Market Cap: 13.92(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $129.52 - $265
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  664
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 100,397 1,200,397 5,371,251 5,588,274
Total Sell Value $15,909,372 $214,459,372 $1,041,558,017 $1,085,894,829
Total People Sold 2 3 8 9
Total Sell Transactions 6 7 21 54
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 241
  Page 5 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Amgen Inc 10% Owner   –       –       •   2020-12-18 4 A $260.95 $6,722,504 D/D 25,762 18,778,273     -
   Amgen Inc 10% Owner   –       –       •   2020-12-17 4 A $260.54 $19,442,507 D/D 74,624 18,752,511     -
   Amgen Inc 10% Owner   –       –       •   2020-12-16 4 A $248.26 $21,244,456 D/D 85,573 18,677,887     -
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2020-12-15 4 GD $0.00 $0 D/D 165,295 5,703,162     -
   Amgen Inc 10% Owner   –       –       •   2020-12-15 4 A $239.31 $16,258,723 D/D 67,941 18,592,314     -
   Liang Howard CFO & Chief Strategy Officer   •       –      –    2020-12-14 4 S $225.24 $21,048,454 D/D (91,900) 0 -42%     
   Liang Howard CFO & Chief Strategy Officer   •       –      –    2020-12-14 4 OE $6.50 $597,350 D/D 91,900 91,900     -
   Liang Howard CFO & Chief Strategy Officer   •       –      –    2020-12-14 4 OE $0.50 $702,650 D/D 1,405,300 1,573,715     -
   Oyler John Chief Executive Officer   •       •      –    2020-12-11 4 GA $0.00 $0 I/I 545,597 545,597     -
   Oyler John Chief Executive Officer   •       •      –    2020-12-11 4 GD $0.00 $0 D/D 2,136,914 6,790,656     -
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2020-12-10 4 GA $0.00 $0 I/I 1,244,542 1,244,542     -
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2020-12-10 4 GD $0.00 $0 D/D 1,332,552 5,868,457     -
   Glazer Donald W. Director   –       •      –    2020-12-04 4 GD $0.00 $0 D/D 589,849 2,907,829     -
   Huang Jane CMO, Hematology   •       –      –    2020-11-30 4 AS $256.00 $401,723 D/D (1,500) 0 15%     
   Huang Jane CMO, Hematology   •       –      –    2020-11-30 4 OE $29.49 $44,235 D/D 1,500 1,500     -
   Huang Jane CMO, Hematology   •       –      –    2020-10-29 4 AS $299.88 $450,093 D/D (1,500) 0 7%     
   Huang Jane CMO, Hematology   •       –      –    2020-10-29 4 OE $29.49 $44,235 D/D 1,500 1,500     -
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2020-10-16 4 AS $320.00 $1,600,000 I/I (5,000) 0 1%     
   Liang Howard CFO & Chief Strategy Officer   •       –      –    2020-10-05 4 AS $293.26 $4,194,413 D/D (14,000) 0 25%     
   Liang Howard CFO & Chief Strategy Officer   •       –      –    2020-10-05 4 OE $6.50 $91,000 D/D 14,000 14,000     -
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2020-10-05 4 AS $300.00 $1,500,000 I/I (5,000) 0 25%     
   Wu Xiaobin President & GM China   •       –      –    2020-10-05 4 AS $300.00 $1,200,000 D/D (4,000) 0 25%     
   Huang Jane CMO, Hematology   •       –      –    2020-09-29 4 AS $274.42 $420,568 D/D (1,500) 0 32%     
   Huang Jane CMO, Hematology   •       –      –    2020-09-29 4 OE $29.49 $44,235 D/D 1,500 1,500     -
   Oyler John Chief Executive Officer   •       •      –    2020-09-29 4 AS $272.74 $6,544,030 D/D (23,303) 0 32%     
  241 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 5 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us